Mouse Resistin ELISA Kit

ELISA Kits|Sandwich ELISA

?-20°C

Competition-based

Quantitative

FIZZ3RETN

Distilled or deionized water
Precision pipettes to deliver 2 µl to 1 ml volumes
Adjustable 1-25 ml pipettes for reagent preparation 100 ml and 1 liter graduated cylinders
Tubes to prepare standard and sample dilutions
Orbital shaker
Aluminum foil
Saran Wrap
Absorbent paper
Microplate reader capable of measuring absorbance at 450nm
Sigma
Plot software (or other software that can perform four-parameter logistic regression models)

Resistin (Adipose tissue-specific secretory factor) (ADSF) (Adipose-specific cysteine-rich secreted protein A12-alpha) (Cysteine-rich secreted protein FIZZ3)

This kit detects Resistin (90aa). No other active isoforms have been reported.Cross Reactivity: This EIA kit shows no cross-reactivity with any of the cytokines tested: Ghrelin, Nesfatin, Angiotensin II, NPY and APC.

Resistin is a 12.5 kDa cysteine-rich hormone secreted by adipose tissue. It is also known as XCP-1 (CEBPE regulated myeloid-specific secreted cysteine-rich protein precursor 1), FIZZ3 (found in inflammatory zone 3), or ADSF (adipocyte-specific secretory factor). The length of the resistin is 108 amino acids in humans, and 114 amino acids in mouse and rat
the molecular weight is ~12.5 kDa. Resistin is an adipokine with physiologic role regarding its involvement with obesity and type II diabetes mellitus (T2DM).Resistin has a high sequence homology among species (43% in a mature protein). Crystal structures of resistin reveal an unusual composition of several subunits that are held together by non-covalent interactions which make up its structure. Each protein subunit comprises a carboxy-terminal disulfide-rich Beta-sandwich "head" domain and an amino-terminal alpha-helical "tail" segment. The globular domain from resistin contains five disulfide bonds.Some studies have shown the important role of resistin linking obesity to T2DM. The underlying belief among those in support of this theory is that serum resistin levels will increase with increased adiposity. Conversely, serum resistin levels have been found to decline with decreased adiposity following medical treatment. This fact takes on significant implications considering the well understood link between central obesity and insulin resistance
marked peculiarities of T2DM. Furthermore, many studies have shown the positive correlations between resistin levels and insulin resistance, and a direct correlation between resistin levels and subjects with T2DM, indicating that such serum resistin increases are accountable for the insulin resistance apparently associated with increased adiposity. In addition to its role in insulin resistance in obese subjects, resistin also plays a role in inflammation and energy homeostasis.